GE HealthCare had its first patient scanned in a phase I clinical trial for an investigational F-18 CD8-targeted PET imaging radiopharmaceutical.
The trial aims to use the radiopharmaceutical to find out if patients have CD8+ T cells in their tumors and perhaps be more likely to respond to immune checkpoint inhibitors. The study will also then help identify early response to immunotherapies, using sequential whole-body imaging to monitor CD8 changes over time.
GE said the F-18 CD8 PET radiopharmaceutical is intended for same-day and subsequent sequential imaging.
